H.C. Wainwright raised the price target for the Clovis Oncology Inc. (NASDAQ:CLVS) stock from “a Buy” to “a Neutral”. The rating was released on May 06, 2022, according to finviz. We previously noted in another research note published on May 18, 2020 by H.C. Wainwright that reiterated the stock to a Buy with a price target of $33 for CLVS stock. The research report from SVB Leerink has downgraded the stock from Mkt Perform to Underperform, with a price target set at $5. The stock was downgraded by BofA/Merrill, who disclosed in a research note on April 09, 2020, from Neutral to Underperform and set the price objective to $6. In their research brief published January 08, 2020, H.C. Wainwright analysts reiterated the Clovis Oncology Inc. stock to Buy with a price target of $27.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Clovis Oncology Inc. (NASDAQ:CLVS) raised 2.32% to close Wednesday’s market session at $0.34, higher as compared to yesterday’s close. The stock price fluctuated between $0.3304 and $0.355 throughout the trading session with the volume trading being 2317927 shares, which represented a significant variation when compared to the three months average volume of 3.97 million shares. The firm’s stock price fluctuated -3.11% within the last five trades and -67.31% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -49.22% in the last 6 months and -73.23% was subtracted to its value over the previous 3 months. CLVS stock is trading at a margin of -48.48%, -64.54% and -76.36% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
As of the close of trading, CLVS deals in the Healthcare domain. The stock is trading -90.03 percent below its 52-week high and 49.78 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -85.86. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Clovis Oncology Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $48.03 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 0.36 that mirrors the cost to be found for sales by the market.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.40 percent of Clovis Oncology Inc. shares are owned by insiders, and 25.90 percent are held by financial institutions. Rolfe Lindsey, the at Clovis Oncology Inc. (CLVS) has sold 4,261 shares of firm on Nov 02 at a price of $0.98 against the total amount of $4188.0. In another inside trade, MUEHL DANIEL W, of Clovis Oncology Inc. (NASDAQ:CLVS) sold 4,579 shares of the firm on Nov 02 for a total worth of $4501.0 at a price of $0.98. An inside trade which took place on Nov 02, of Clovis Oncology Inc. Harding Thomas C. sold 63 shares of firm against total price of $62.0 at the cost of $0.98 per share.